POST-GRAFTING HEALTHCARE AFTER KIDNEY TRANSPLANT

POST-GRAFTING HEALTHCARE AFTER KIDNEY TRANSPLANT It is now well established that early kidney transplantation is associated with optimal outcomes in terms of patient and graft survival. In chronic kidney disease (CKD) - Stage V patients kidney transplantation is considered as the treatment of choice because both survival and quality of life are often better than in people who are treated with dialysis. After kidney transplantation patients receive a combination of immunosuppressive medications to prevent rejection of the transplanted kidney. Newer immunosuppressive drug regimens have resulted in improving the outcomes in kidney transplantation in the last two decades. These regimens usually contain a (CNI) calcineurin-inhibitor (tacrolimus or cyclosporine) steroids along with antiproliferative agent mycophenolate mofetil (MMF).The introduction of azathioprine as an effective oral immunosuppressant in the late 1950s resulted in achieving the first long-term survivors of transplants between genetically non-identical individuals (allografts). This drug acts by inhibiting purine synthesis.